Altria's $13B Juul investment has lost 95% of its value
Altria reports its nearly $13 billion investment in troubled vaping company Juul is worth 95% less than it originally paid
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Cigarette maker Altria's $13-billion investment in the troubled vaping company Juul has gone up in smoke — now worth less than 5% of its original value as U.S. regulators move to ban its e-cigarettes.
Altria slashed the value of its Juul investment again Thursday, pegging its value at under $500 million as it reported second-quarter earnings. Previously, the Marlboro maker had valued its stake in the company at $1.6 billion.
Despite the losses Altria said it was maintaining its investment deal with Juul, including an agreement not to market competing vaping products.
“At this time, we continue to believe that these investment rights are beneficial to us,” Altria said in a prepared statement.
Altria, based in Richmond, Virginia, is Juul’s largest investor with a 35% ownership stake. Altria executives signed the $12.8-billion pact in 2018, betting that Juul’s popular vaping devices represented a lucrative new opportunity in the vaping market.
But last month the U.S. Food and Drug Administration announced plans to ban the small cartridge-based e-cigarettes, saying Juul had failed to provide key information about potentially harmful chemicals in its nicotine formula. The decision surprised industry observers and experts given that the FDA has authorized several competing e-cigarettes and Juul spent years gathering data to support its application.
In yet another twist to the company’s fortunes, the FDA reopened its review of Juul’s application earlier this month after a federal court blocked the ban from immediately taking effect. For now, Juul is able to continue selling its products while the FDA review continues.